Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-661 plus ivacaftor in cystic fibrosis with homozygous F508del mutation
NL-OMON42785Phase 3Not yet recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cystic fibrosis (CF) comparing VX-661 + ivacaftor with Placebo control (2 arms). Primary endpoint: Absolute change in percent predicted forced expiratory volume in 1 second. Planned start Aug 2015; status: not yet recruiting.
02
Drugs
tezacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON42785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42785.